Cirrhosis of the Liver Clinical Trial
Official title:
Health-Related Quality of Life in the Low Model for End-Stage Liver Disease (MELD) Pre Transplant Patient Candidate: A Pilot Study
The purpose of this study is to describe the HRQoL in those with MELD scores </= 15 in a single center for those who are pre-liver transplant candidates
The liver organ allocation system was significantly revised in 2002, allowing a more objective prioritization of liver transplant candidates. The revised Model for End Stage Liver Disease (MELD) system is based primarily on laboratory test results. Candidates with MELD scores of less than 15 are considered to be low priority for cadaveric liver transplant and have limited treatment options. Yet patients with low MELD scores may suffer from an array of symptoms associated with liver disease such as fatigue, sleep disturbances, and depression - all of which erode health-related quality of life (HRQoL). No previous studies were found that examined HRQoL in low MELD transplant patients. A better understanding of the HRQoL of these patients will allow clinicians to better meet their needs. Therefore, the aims of the proposed pilot capstone project are to examine HRQoL and to identify demographic and clinical characteristics including liver-disease related symptoms, functional status, perceived social support, biological functioning and mental health associated with HRQoL in pre-liver transplant candidates with low MELD scores. The revised Wilson and Cleary Quality of Life Model will be used to guide the project. Fifty pre-transplant liver candidates with MELD scores < 15 will be enrolled in the descriptive, cross-sectional pilot study. Participants will complete a written questionnaire measuring perceived HRQoL and clinical characteristics. Descriptive and correlational statistics will be used to analyze the data. Findings from this project will identify trends in factors that contribute to a HRQoL of this population and provide the foundation for a larger future project. ;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05178303 -
Composition for Treating Cirrhosis and Liver Cancer (SB-1121)
|
N/A | |
Enrolling by invitation |
NCT06121492 -
Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia
|
Phase 3 | |
Completed |
NCT04243148 -
Frailty in Patients With Cirrhosis: Prognostic Value of the Phase Angle in Hospitalized Patients and Effect of Multifactorial Intervention
|
N/A | |
Completed |
NCT02862249 -
Trial of Faecal Microbiota Transplantation in Cirrhosis
|
Phase 3 | |
Completed |
NCT02608658 -
Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites
|
N/A | |
Withdrawn |
NCT02809248 -
The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)
|
N/A | |
Recruiting |
NCT04116242 -
MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease
|